RTC-5 demonstrated efficacy against a xenograft model of an EGFR driven cancer without the neurotropic effects exhibited by the parent molecules. Its effects were attributed to concomitant negative regulation of PI3K-AKT and RAS-ERK signaling
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | 6-8 weeks | $ 127 | |
10 mg | 6-8 weeks | $ 228 | |
20 mg | 6-8 weeks | $ 301 | |
50 mg | 6-8 weeks | $ 728 | |
100 mg | 6-8 weeks | $ 1150 |
Description | RTC-5 demonstrated efficacy against a xenograft model of an EGFR driven cancer without the neurotropic effects exhibited by the parent molecules. Its effects were attributed to concomitant negative regulation of PI3K-AKT and RAS-ERK signaling |
Targets&IC50 | EGFR: |
CAS No. | 1423077-49-9 |
Chemical Formula | C24H22ClF3N2O3S |
Molecular Weight | 510.96 |
Solubility | DMSO: 15 mg/mL (29.36 mM), Need ultrasonic |
Storage | Powder: -20°C for 2 years In solvent: -80°C for 1 year |
bottom